iran primary plasticizer diisobutyl phthalate DIBP

iran primary plasticizer diisobutyl phthalate DIBP

toxicity review of diisobutyl phthalate (dibp) cpsc

iran primary plasticizer diisobutyl phthalate DIBP

hazards of diisobutyl phthalate (dibp) exposure: a systematic

iran primary plasticizer diisobutyl phthalate DIBP

toxicity review of diisobutyl phthalate (dibp) researchgate

iran primary plasticizer diisobutyl phthalate DIBP

diisobutyl phthalate (dibp)-induced male germ cell toxicity

iran primary plasticizer diisobutyl phthalate DIBP

risk evaluation for di-isobutyl phthalate (1,2-benzene

iran primary plasticizer diisobutyl phthalate DIBP
  • What is Diisobutyl phthalate (DIBP)?
  • Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). ?) Diisobutyl phthalate (DIBP) is a phthalate ester having the structural formula C6H4(COOCH2CH (CH3)2)2. It is formed by the esterification of isobutanol and phthalic anhydride.
  • How is dibutyl phthalate excreted?
  • When it comes to excretion, DIBP is first converted into the hydrolytic monoester monoisobutyl phthalate (MIBP). The primary excretory route is urine, with biliary excretion being noted in minor amounts. DIBP has lower density and freezing point than the related compound dibutyl phthalate (DBP).
  • Does Diisobutyl phthalate impair androgen-dependent reproductive development of male rat?
  • "Diisobutyl phthalate impairs the androgen-dependent reproductive development of the male rat". Reproductive Toxicology. 26 (2): 107–115. Bibcode: 2008RepTx..26..107S. doi: 10.1016/j.reprotox.2008.07.006. PMID 18706996.
  • What is the s2cid for Diisobutyl phthalate?
  • ISSN 2211-7156. S2CID 240582041. ^ "Metabocard for Diisobutyl phthalate". The Human Metabolome Database (HMDB).
  • How does DIBP affect fetal gynecology?
  • AGD was reduced at GD 19 and GD 20/21 in males and increased in females exposed to DIBP. It also reduced bodyweights of male and female fetuses. Reduced maternal body weight gain from 73 g in controls to 48 and 43 g in the 600 and 900 mg/kg/day dose groups, respectively. Reductions in fetal plasma leptin levels and in fetal insulin levels.